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Title: Parkinson’s disease and the gastrointestinal microbiome.

Abstract:
Recently, there has been a surge in awareness of the gastrointestinal microbiome (GM) and its role in
health and disease. Of particular note is an association between the GM and Parkinson’s disease (PD)
and the realisation that the GM can act via a complex bidirectional communication between the gut and
the brain. Compelling evidence suggests that a shift in GM composition may play an important role in
the pathogenesis of PD by facilitating the characteristic ascending neurodegenerative spread of α–
synuclein aggregates from the enteric nervous system to the brain. Here, we review evidence linking
GM changes with PD, highlighting mechanisms supportive of pathological α-synuclein spread and
intestinal inflammation in PD. We summarise existing patterns and correlations seen in clinical studies
of the GM in PD, together with the impacts of non-motor symptoms, medications, lifestyle, diet and
aging on the GM. Roles of GM modulating therapies, including probiotics and faecal microbiota
transplantation are discussed. Encouragingly, alterations in the GM have repeatedly been observed in
PD, supporting a biological link and highlighting it as a potential therapeutic target.
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Introduction:
Parkinson’s disease (PD) is an incurable and progressive neurodegenerative disorder, affecting 1-2 per
1000 (0.4-2.0% of people above the age of 65) of the population worldwide [1]. PD is a multisystem
disorder that contributes to significant morbidity and healthcare burden [2, 3]. It is predominantly
associated with the irreversible degeneration of dopaminergic neurons in the substantia nigra and other
brain regions [4], often characterised by widespread Lewy Body (LB) formation in the central and
peripheral nervous systems. Features characteristic of clinical disease include tremor, rigidity,
bradykinesia and postural instability [5]. Premotor and non-motor symptoms of PD include
constipation, hyposmia, REM-sleep behaviour disorder (RBD), as well as cognitive, neuropsychiatric,
autonomic and sensory disturbances [6]. These symptoms can emerge years, or even decades, prior to
the manifestation of motor symptoms, but often go unrecognised [7].

Recently, the human gastrointestinal microbiome (GM) has been proposed to be an integral link for the
pathogenesis of many neurodegenerative diseases [8]. Evidence exists for a bidirectional interaction
between the GM and the central nervous system (CNS), known as the ‘microbiota-gut-brain axis’
(MGBA) [9]. Multiple MGBA pathways exist, including microbially-produced molecules with neuroendocrine activity (e.g. serotonin, gamma-Aminobutyric acid) [10] and CNS-regulated physiological
functions, such as intestinal motility influence on the microbial ecosystem [11]. These connections
create a feedback loop between human physiological and microbial community states, forming the
basis for neurodegenerative diseases of dysbiosis. Consequently, dysbiosis of the GM portrays an
interesting lead to explore in the pathogenesis of PD [12, 13] and presents as a novel diagnostic and
therapeutic target [14].

The Human Gastrointestinal Microbiome
The human GM contains in the order of 1 × 1014 bacteria [15], with a biomass comparable to the
human brain at 1-2 kilograms [16]. The GM predominantly comprises Bacteria, but also Archaea,
Fungi, Viruses and other simple eukaryotic organisms [8]. However, the metabolic activity of the GM
is overwhelmingly dominated by Bacteria. Their primary role is to anaerobically breakdown
carbohydrates that are incompatible with human digestive processes. Other cellular microbes contribute
other specific metabolic activities (e.g. methanogenesis by Archaea) and bacteriophage viruses
modulate the genetic background of bacterial growth in the gastrointestinal tract.
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Establishment of the GM begins at birth and is vital for postnatal immune and Enteric Nervous System
(ENS) development [17]. The GM also forms an integral defence barrier against potentially hazardous
external stimuli and is highly adaptive with regard to changes in diet, lifestyle and the surrounding
environment [18]. Diet, exercise, probiotic supplements and changes in hygiene, can modify the
composition of the GM [19], as can recolonisation following antibiotics and invasive pathogenic
colonisation [20]. Despite constant environmental variation in the gut, the GM composition remains
relatively stable during adulthood [21]. Although in some instances, dietary changes have been shown
to induce variability over 3-4 days [22].

Gut Microbiome and the Nervous System
The MGBA connects the gastrointestinal tract to the CNS [23, 24], with neurosynaptic pathways of the
vagal nerve, autonomic and enteric fibres, in addition to various neuroendocrine and neuroimmune
pathways, mediating its integrity [25]. Under physiological conditions, the MGBA is a major
participant in signalling pathways that regulate digestive function and metabolic homeostasis.
However, various mechanisms that disrupt these pathways can perturb cognition, behaviour, learning,
pain and neuropsychiatric features (including anxiety, depression and even neurodevelopmental
disorders, such as autism) [15, 26-28]. It has been suggested that dysregulation of the MGBA may
directly influence PD pathogenesis, with progressive neurodegeneration from the gut to the brain
occurring as a consequence of ascending alpha-synuclein (α–Syn) aggregation and LB formation
(Figure 1) [29].

The GM influences neuronal network health and activity by facilitating the absorption of nutrients,
vitamins and medications, as well as modulating the immune system [30] and moderating neurotoxic
compounds (e.g. ammonia and D -lactate) [31]. It is also independently capable of neurotransmitter
synthesis, including dopamine, noradrenaline, serotonin and the neuromodulators γ-aminobutyric acid
and short-chain fatty acids (SCFAs) [10, 32-34]. These neurotransmitters act to modulate blood flow,
affect gut motility and nutrient absorption, as well as supporting the gastrointestinal innate immune
system [35]. As an example, dopamine synthesis in the brain is mediated by catecholamine-producing
enzymes that are governed by the GM via the MGBA, producing half of the body’s required dopamine
[36]. Accordingly, this intricate network shares a crucial role in maintaining the vital physiological
interplay between the gastrointestinal tract and the brain [37].

Braak's Hypothesis for Parkinson’s Disease
Common clinical features of gastrointestinal dysfunction in PD include abnormal salivation, dysphagia,
nausea, impaired gastric emptying and constipation, and occur in 80% of patients [30, 38]. Several
large population studies have shown that constipation can precede motor symptoms of PD by up to 20
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years, and increases the risk of developing PD [39, 40]. Consistent with the clinico-epidemiological
observations, several neuropathological studies have found early accumulation of LBs in the ENS and
dorsal motor nucleus of the vagus, with correlations to motor and gastrointestinal symptom severity
[41, 42].
Braak and colleagues proposed a “dual-hit hypothesis”, where α–Syn aggregation commences outside
of the brain, within the ENS and olfactory bulb, precipitated by external insults such as toxins and/or
microorganisms [43]. They suggested that neuronal α–Syn deposition occurs in a caudorostral gradient,
affecting the dorsal motor nucleus of the vagus nerve before progressing to the dopaminergic neurons
of the substantia nigra [43]. However, this hypothesis remains controversial, as some studies were
unable to replicate the caudorostral progression [44, 45]. Despite this, in support of Braak’s findings,
α–Syn has been shown to exhibit prion-like properties, with the ability to misfold, form aggregates and
propagate from cell to cell [46, 47]. Further evidence from follow-up cohort studies in Danish [48] and
Swedish [49] populations showed that only a full truncal vagotomy could decrease the risk of
developing PD compared to a control population. The level of significance was further diminished
when the dataset was analysed by an independent research group [45, 50]. In addition, hemivagotomy
in a PD mouse model prevented α–Syn accumulation in the ipsilateral dorsal motor nucleus of the
vagus [51]. Interestingly, a recent large Swedish database study suggested those with an appendectomy
early in life had a 20% reduced risk of developing PD [52]. Despite these findings, phosphorylated α–
Syn accumulation in the intestine is not a specific hallmark of PD, having been observed in patients
with Lewy Body dementia, Alzheimer’s with Lewy Bodies and asymptomatic controls [53]. Thus, what
constitutes pathological α–Syn species in the gut remains ill defined [54].

Inflammation and Gut Permeability
A critical aspect of host-microbiome interaction is the barrier functions of the gut epithelium [55].
Disruption of the barrier can trigger positive feedback loops involving intestinal inflammation, reactive
oxygen/nitrogen species in the gut lumen and a shift in microbial composition favouring
inflammophiles [56, 57]. Key to aberrant GM influence through the MGBA is destabilisation of the
protective gastrointestinal barrier, resultant of translocation of bacteria or their products, such as
lipopolysaccharides. This leads to oxidative stress and intestinal inflammation, which induces increased
mucosal permeability [30, 58], as well as α–Syn aggregation in the ENS [59-61].
Intestinal permeability or ‘gut leakiness’ has been shown to be increased in PD patients compared to
healthy controls [62-64] and mouse models of PD [65], correlating with an increase in enteric α–Syn
deposition and tissue oxidative stress [62]. However, findings suggestive of increased intestinal
permeability in PD require cautious evaluation. For example, Clairembault et al. showed that the
intestinal epithelial barrier was morphologically altered in PD but showed no change in the
permeability of the intestinal epithelial barrier [55]. Despite this, other disorders known to have
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increased intestinal permeability, such as inflammatory bowel disease, have recently been associated
with an increased risk of PD. This further supports a role for gastrointestinal inflammation in the
development of PD [66-68]. Moreover, priming of the gastrointestinal innate immune system by the
GM can strengthen the inflammatory response to α–Syn [11].
Microbes vary in their cell structure and propensity to initiate pattern-recognition receptor signalling
pathways, leading to inflammation. Evidence suggests that increased levels of Escherichia coli [62]
and the proteobacteria Ralstonia [69], as well as lower plasma lipopolysaccharide-binding protein [70],
reflect higher endotoxin exposure and drive intestinal inflammation. This inflammation is characterised
by increased expression of the pro-inflammatory cytokines TNF-alpha, IFN-gamma, IL-6, and IL-1
beta, as well as an increased activation of enteric glial cells, consistent with colonic biopsies of PD
patients [60]. Moreover, Perez-Pardo et al. suggested that Toll-like-receptor-4 signalling pathways may
be implicated in facilitating intestinal inflammation, disrupting the intestinal barrier and facilitating
neuro-inflammation, as shown in PD patients and a PD mouse model [71].

Further, SCFAs (acetate, propionate and butyrate) are major metabolic products of the GM, with lower
faecal SCFA concentrations reported in PD patients compared to healthy controls [72]. SCFAs have
multiple impacts, with nutritional and signalling roles being especially important in humans [73]. In
particular, butyrate is a major energy substrate for colonocytes, playing an important role in gut health
processes, such as mucin production and tight-junction formation [74]. Beyond their nutritional role,
SCFAs are also a primary target for several G-protein-coupled receptors that feed into
immunometabolic regulatory circuits. The relative concentration and distribution of SCFA types has
profound influence over gut function and homeostatic processes.

Several studies have indicated a decreased abundance of Lachnospiraceae in PD patients [69, 75, 76],
known for their abundant production of SCFAs. Sampson et al., suggested that SCFAs were a major
factor inducing microglial activation and accelerating α–Synucleinopathy in mouse models, thus
enhancing PD pathophysiology [77, 78]. However, depletion of SCFA-producing organisms in the gut
has been observed in a variety of other conditions, suggesting this may be a marker of illness or
associated with aging [72], rather than a specific cause or biomarker of PD [75]. Consistently,
controversy remains over the validity of decreased SCFAs leading to a pro-inflammatory gut
environment in PD [78].

Gut Infections in Parkinson’s Disease
The role of Helicobacter pylori in gastritis and dyspepsia is well known. However, in PD, it also
appears to be associated with greater severity of motor features [79]. Several studies have suggested
that antimicrobial treatment for H. pylori could improve PD motor symptoms and motor response
complications, as well as levodopa absorption and bioavailability [80]. However, a Cochrane review
concluded that current evidence remained insufficient to recommend H. pylori eradication in PD, due
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to a lack of informative clinical trials [81]. The prevalence of small intestinal bacterial overgrowth is
estimated to range from 25-54% in PD [82, 83] and is associated with worse motor severity [83],
longer daily off times and more episodes of delayed-on and dose failures [84]. A small-randomised
controlled trial suggested that small intestinal bacterial overgrowth eradication in PD could result in
improved motor fluctuations, without affecting the pharmacokinetics of levodopa [84].

Associations Between Gastrointestinal Microbiota Community Structure and Parkinson’s
Disease
Over the last 4-years there have been numerous studies exploring the association between GM and PD,
stimulated by greater awareness of gastrointestinal dysfunction in prodromal and early PD, as well as a
better understanding of the MGBA [85, 86]. To date, 14 mainly cross-sectional studies from 7 countries
in the northern hemisphere have reported GM alterations in PD [12, 13, 69, 70, 72, 75, 76, 87-93]. At
the level of taxonomic profiles, no obvious recurrent pattern is seen in these studies. However,
emerging trends show correlations between GM alterations in PD and a variety of motor and non-motor
symptoms [94]. Considerable variability in the patient inclusion/exclusion criteria, molecular,
bioinformatic and statistical methodologies between the studies were apparent and are summarised in
Table 1. Most studies employed bacterial 16S ribosomal DNA amplicon sequencing of different
variable regions to identify bacterial groups/genera/species, with three studies using targeted
quantitative PCR to analyse preselected bacterial taxa, and one utilised metagenomic shotgun
sequencing. PD patient cohort sizes ranged from 24 to 197 individuals, with all but one study
comparing to a healthy control group. Exclusion of participants for use of antibiotics within 1-month of
sample collection was generally observed. Only one study reported on longitudinal GM differences
with a comparison at 2-year follow-up in 28 patients [13].

Each of the studies found significant differences between PD and healthy control groups, and
collectively showed significant differences in the overall faecal GM composition in PD patients when
compared to non-PD controls. In spite of this, it is not certain whether these changes are the cause or
consequence of the gastrointestinal dysfunction associated with PD. Recent evidence from HeintzBuschart et al. suggests that GM alterations likely pre-date the motor symptoms of PD [88]. The
highest number of microbiota abundance differences between PD and controls was reported in the
phylum Firmicutes [95], the largest phylum in the human GM. Specifically, increased Lactobacillaceae
(family) and Lactobacillus (genus) and decreased Lachnospiraceae (family), Blautia, Roseburia,
Dorea and Faecalibacterium (genus) were observed. The most consistent differences were reported in
the phylum Verrucomicrobia, principally increased Verrucomicrobiaceae (family), Akkermansia
(genus) and Akkermansia muciniphila (species). Moreover, significant changes in abundance of the
phylum Bacteroidetes were also reported, with reductions in Prevotellaceae (family), Prevotella
(genus) and Prevotella copri (species) (Table 1). Some studies deduced that putative “pro-
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inflammatory” bacteria were significantly more abundant, while putative beneficial bacteria were less
abundant in PD [69].

Several studies have evaluated predicted functional differences based on faecal GM metagenomics data
and suggested alterations of several metabolic pathways in PD, when compared to non-PD controls [69,
75, 91]. Kershavarzian et al. showed that a large number of genes involved in metabolism were
significantly lower in the PD faecal microbiome, whereas genes involved in lipopolysaccharide
biosynthesis and type III bacterial secretion systems were significantly higher in PD patients [69]. HillBurns et al. found alterations in pathways involved in carbohydrate, energy, lipid, cofactor, vitamin and
xenobiotic metabolism, as well as xenobiotic biodegradation [75]. The only study that utilised a very
comprehensive metagenomics shotgun analysis, found differences in microbiota metabolism in PD
involving the β-glucuronate and tryptophan metabolism pathways [91]. Furthermore, metabolite studies
reported reduced levels of serum lipopolysaccharide-binding protein [70, 96] and faecal SCFA [72] in
PD patients.
Evaluating atypical parkinsonism, Barichella et al. suggested the overall gut microbiota composition in
multiple system atrophy (MSA) and progressive supranuclear palsy were not significantly distinct
when compared to PD [76]. Moreover, changes in several bacteria taxa when compared to controls,
were similar to PD [76], whilst drug naïve PD patients had lower abundances of Lachnospiraceae when
compared to controls [76]. In another MSA GM study, higher relative abundances of gram-negative,
putative ‘pro-inflammatory’ bacteria from the phylum Bacteroidetes and Proteobacteria were noted in
faecal and mucosal samples, whilst putative ‘anti-inflammatory’ butyrate-producing bacteria were less
abundant. Further, the relative abundance of a number of genes involved in metabolism were lower in
faecal material from patients with MSA, whilst the relative abundance of genes involved in
lipopolysaccharide biosynthesis were higher in MSA patients compared to healthy controls [97].
Several bacteria taxa have been associated with various motor response complications and worse motor
severity in PD (Table 2).
Significant differences were also found in the GM composition of sigmoid mucosa in PD when
compared to controls, although differences were more pronounced in faecal versus mucosal samples
[69]. Comparison of nasal microbiota between PD patients and controls did not yield significantly
different results, limiting the utility of a nasal microbiota biomarker in PD [88, 98]. One study on oral
microbiota found significant differences in overall composition between PD patients and controls and,
interestingly, a higher abundance of Prevotellaceae in PD, contrary to the previous findings in the
faecal microbiome [98]. Lastly, increased abundance of Anaerotruncus and reduced relative abundance
of Prevotellaceae were shown in patients with idiopathic RBD, suggesting a possible prodromal GM
change in PD [88].
Of great interest is the pioneering work by Samson and colleagues, who have provided the strongest
evidence to date for a causal role of GM alterations in PD. These investigators showed that
transplantation of gut microbiota from six PD patients to transgenic mice over-expressing α–Syn
resulted in worsening of clinically-relevant motor deficits [77]. Additionally, mice raised in a germ-free
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environment developed little PD-related pathophysiology, including motor dysfunction,
neuroinflammation and α–Syn pathology [77]. They hypothesised that the clinical effects of gut
microbiota were primarily mediated by SCFAs, enabling the activation of microglia and potentially
leading to increased neuroinflammation and subsequent exacerbation of PD. Furthermore, they
demonstrated that the oral administration of SFCAs in a germfree PD mouse model resulted in
prominent motor symptoms [77].

Non-motor Symptoms and the Gastrointestinal Microbiota
Non-motor symptoms (NMS) generally predate motor features in PD, reflecting degeneration of extranigral areas prior to involvement of the substantia nigra. Common NMS include disrupted sleep
architecture (particularly with RBD), impaired olfaction, behavioural changes, as well as impaired
visuospatial abilities and executive function [99]. There is growing evidence of altered GM
composition in various PD-related NMS, in addition to other psychiatric disorders, namely anxiety and
depression, which are highly prevalent in PD [100]. Recently, it was identified that changes
in Anaerotruncus, Akkermansia and several other unclassified bacteria were significantly related to
NMS according to MDS-UPDRS part I [88] (Table 2). For instance, an altered abundance
of Anaerotruncus spp. was related to depression in PD [88] and patients with anxiety had a higher
abundance of Clostridium clariflavum compared to those without anxiety [101]. Furthermore, those
with moderate depression were suggested to have higher relative abundance of Christensenella minuta,
Clostridium disporicum and Oscillibacter valericigenes compared to those without depression or with
mild depression [101]. In other PD studies, depression was also associated with the genera
Anaerotruncus spp [88]. Studies outside of PD have identified significant changes in the GM
composition in those with depression. Depression and PD frequently coincide, with depression often
contributing significantly to impairment of health-related quality of life in PD [102]. Jiang et al.
showed that those who were acutely depressed had higher levels of Bacteroidetes,
Proteobacteria and Actinobacteria, and lower levels of Firmicutes; a negative correlation
between Faecalibacterium and the severity of depression was also described [103].

Gastrointestinal symptoms are one of the most common PD NMS, involving the entirety of the
gastrointestinal tract and evident throughout the whole disease course [104]. Patients with PD and
Irritable Bowel Syndrome (IBS)-like symptoms have been shown to feature more NMS, as well as a
lower faecal abundance of Prevotella bacteria than those without IBS-like symptoms [86].
Constipation, a cardinal NMS of PD, has also been shown to predispose to GM alterations, along with
increased mucosal permeability and inflammation [105]. Cognitive changes have been linked to varied
GM compositions in PD, with positive associations in the abundance of Butyricicoccus and Clostridium
XIVb described [90]. In a 2-year longitudinal study, lower counts of Bifidobacterium and Bacteroides
fragilis at baseline were associated with worsening hallucinations and delusions, and worsening
motivation and initiative [13], respectively.
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Parkinson’s Disease Medications and the Gastrointestinal Microbiome
An extensive range of medications have been proposed to influence the composition of the GM,
including several PD medications [106]. One study reported that treatment with standard PD
treatments, catechol-O-methyltransferase (COMT) inhibitors and anticholinergics, resulted in a
difference in the composition of the GM, independent of the PD effect [75]. COMT inhibitor usage was
also shown to be significantly associated with increased abundance of Lactobacillaceae and reduced
abundance of Clostridiales Incertae Sedis IV [12]. The isolated effects of levodopa/carbidopa were
difficult to identify due to ubiquitous usage by PD patients [75]. However, levodopa appeared to be
significantly associated with Bacillaceae abundance in one study [88]. Qian et al. suggested that the
levodopa equivalent daily dose was negatively associated with the genera Dorea and
Phascolarctobacterium. Furthermore, Bedarf et al. commented that the use of monoamine oxidase
inhibitors, amantadine or a dopamine agonist had no overall influence on taxa abundance or microbial
function [91]. Significantly, reduced abundance of Prevotella, reported by several PD-GM studies,
could not be explained by PD medications, and was observed in levodopa naïve early-stage PD patients
[91]. Importantly, other significant between-group differences in the GM were observed between drugnaïve and treated PD patients [69]. Interestingly, no studies have specifically evaluated the GM
composition in advanced disease patients requiring device-assisted therapies, highlighting a need for
more studies in pre-treated PD patients. Hopfner et al. reported that in their cohort of 29 PD patients, 6
were treated with deep brain stimulation, although no GM subgroup analysis was provided.

Lifestyle Influences and Other Potential Confounders of the Gastrointestinal Microbiota in
Parkinson’s Disease
There is increasing evidence that certain lifestyle factors contribute to PD pathology. Increased urate
levels have been shown to provide a protective effect through antioxidant activity, conferring a 33%
risk reduction for PD [107]. Furthermore, although debated, epidemiological studies suggest a smoking
history may confer approximately 60% reduced risk of developing PD, whilst coffee consumption was
found to reduce the risk by 30% [108, 109]. These neuroprotective effects are likely mediated through
nicotinic acetylcholine and adenosine A(2A) receptor-mediated activity [30], or through prevention of
α–Syn misfolding and fibril formation [110]. Derkinderen et al. suggested that the beneficial effects of
smoking and coffee consumption in PD risk could be mediated through the MGBA, specifically by
altering the composition of the GM in ways that mitigate intestinal inflammation, thus reducing α–Syn
misfolding and deposition [111]. This hypothesis was supported by a study in humans showing gut
dysbiosis after smoking cessation [112], with smokers having a higher abundance of faecal Bacteroides
and Prevotella. After smoking cessation, a decreased abundance of Proteobacteria and an increased
abundance of Firmicutes and Actinobacteria were observed [112].
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Effects of coffee consumption may relate to its composition of alkaloids, phenolic compounds, fibres
and minerals [30]. SCFAs that arise from coffee’s dietary fibre metabolism may cause an expansion of
Bacteroides and Prevotella bacteria [113]. Coffee consumption can also increase the abundance of antiinflammatory Bifidobacteria and decrease Clostridium spp. and Escherichia coli [114, 115].
Furthermore, consumption of alcohol-containing products, coffee, tea and sugar-sweetened drinks
show correlation with altered microbial compositions. For instance, red wine consumption correlates
with an increased abundance of F. prausnitzii, known for its anti-inflammatory functions [116].
Furthermore, coffee, tea and red wine consumption have been associated with increased GM diversity
[117], supporting lifestyle modification in the influence of PD predisposition.

Stress has also been suggested to promote gut leakiness and affect the microbiota community
abundances in several animal and human studies [118, 119]. A recent study by Dodiya et al. showed
that stress exacerbated intestinal inflammation, gut leakiness, endotoxema, neuro-inflammation and
dopamine loss, in a PD mouse model [120].

Macronutrients, particularly carbohydrates, have also been shown to influence the composition and
function of the GM [121]. For instance, individuals consuming more plant carbohydrates and fibre had
a higher abundance of Prevotella/Paraprevotella, compared to those consuming predominantly animal
fat and protein who harboured more of the Bacteroides enterotype [122]. Fibre-rich diets appear to
enhance the growth of colonic bacteria producing SCFAs, which in turn confer systemic antiinflammatory effects [72]. For instance, Prevotella, which has been shown at lower abundance in PD
[12], is an important contributor to gut SCFA synthesis, as well as folate and thiamine biosynthesis
[123], nutrients known to be deficient in PD [124].

Further, the Western diet is known to be high in refined carbohydrates and saturated fats, which may
result in a dysbiotic GM, with lower Bifidobacteria, higher Firmicutes and proteobacteria [125]. Highfat diets have also been shown to induce intestinal and systemic inflammation in animal models by
increasing intestinal permeability and altering the GM [126]. Consumption of dairy products has been
suggested to variably affect the risk of PD [109]. Drinking sour milk with a lower fat content has been
associated with higher GM diversity of beneficial Leuconostoc mesenteroides and Leuconostoc lactis,
whilst drinking whole milk was associated with lower diversity [116]. Furthermore, studies evaluating
urate metabolism suggested that Prevotella-dominant enterotypes were associated with higher serum
urate levels [12].

The effects of age and exercise have also been described in relation to the GM. Age-related changes in
the GM reflect decreased diversity of species [127], with corresponding decreases in microbial
functional abundance [116]. Biagi et al. suggested that aging was associated with increasing abundance
of subdominant species, including rearrangement in their co-occurrence networks [128]. A significant
reduction in the abundance of Lactobacilli, Bacteroides/Prevotella and Faecalibacterium prausnitzii
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and an increased abundance of Ruminococcus, Atopobium and Enterobacteriaceae were reported in
individuals with high frailty scores [129]. Elderly community-dwelling residents were noted to share a
more diverse GM and were healthier compared to those in short or long-term residential care [130],
reflected by greater inter-individual GM variation, as well as significant relationships between the GM,
diet and differences between community and institutional living [131].

Exercise has also been associated with favourable changes in the GM composition, influencing energy
homeostasis and regulation [132]. Physical exercise has been suggested to enhance the number of
beneficial bacterial species, enrich microbial diversity and improve the development of commensal
bacteria, irrespective of diet [132, 133]. Estaki et al. found that fitter individuals had a GM enriched in
butyrate-producing taxa, including Roseburia, Clostridiales, Lachnospiraceae and Erysipelotrichaceae,
favouring optimal gut health and improved metabolism [133].

Antibiotics, not surprisingly, have been shown to induce significant changes in the GM, as well as in
dopaminergic signalling [134]. Antibiotic therapy affects the diversity of the GM and is associated with
reduced abundance of Bifidobacteria, as well as Bacteroides and Prevotella groups [130]. Minocycline
has shown neuroprotective efficacy in PD animal models, by limiting nigrostriatal neurodegeneration,
as well as blocking dopamine depletion in the striatum and nucleus accumbens [135]. Other studies
have also suggested minocycline-related antioxidant and anti-inflammatory properties confer
dopaminergic neuroprotection [136]. Minocycline has been further shown to re-balance GM dysbiosis
in a hypertension model, by reducing the Firmicytes:Bacteroidetes ratio [137]. Although, no studies
have been conducted to directly evaluate minocycline’s effect on the GM in PD patients [15].
Furthermore, minocycline is implicated in modulation of depression, likely due to anti-inflammatory
properties and neuroprotective roles [138]. Conversely, minocycline has been suggested to have
deleterious effects in PD animal models [139].

Other antibiotics, including ampicillin, ceftriaxone, neomycin, metronidazole and polymyxin B, have
also shown potential neuroprotective mechanisms or result in clinical disease changes via MGBA
interactions [15]. Potential mechanisms suggest decreased physical activity, as well as modulation of
GM abundances, as potential considerations [140]. Despite these small, mainly animal-based studies
describing interesting interactions with antibiotic use and the neurobiology of GM-PD, further human
clinical trials are required to investigate potential antibiotic influences on the MGBA.

Potential Roles of Prebiotics and Probiotics in Parkinson’s Disease
Emerging interest evaluating prebiotic and probiotic use in PD and other neuropsychiatric disorders is
providing valuable insight into potential novel mechanisms aimed at favourably modifying various
symptoms. Consumption of fermented milk containing Lactobacillus casei Shirota for five-weeks was
shown to improve stool consistency and reduce bloating and abdominal pain in patients with PD [141].
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A more recent randomized controlled trial showed that intake of fermented milk containing probiotic
strains and prebiotic fibre significantly increased the frequency of complete bowel movements in PD
patients [142]. Probiotic studies have reported beneficial health effects by a variety of mechanisms,
including enhancing intestinal epithelial integrity, protecting against barrier disruption, stimulating a
healthy mucosal immune system and suppressing pathogenic bacterial growth [143].

Human studies are beginning to show that probiotics may be effective in reducing depression and
anxiety-like symptoms [144], with those receiving probiotics having higher numbers of faecal gut
microbial species and lowered levels of Bacteroidaceae compared to healthy controls [145]. Improving
gastrointestinal function with probiotic supplementation may also potentially improve levodopa
absorption [143], and reduce behavioural and cognitive deficits commonly observed in PD, such as
anxiety, depression and memory problems [146]. Prebiotics, which include dietary soluble fibres, such
as galactooligosaccharides or fructooligosaccharides, can stimulate the growth of intrinsic commensal
microbiota and have also been keenly studied for their effects on mood [147]. Recent prebiotic studies
have shown promising anxiety-modifying effects after consumption of certain dietary soluble fibres
[148] and fermented foods [149], suggesting anxiolytic efficacy. Therefore, probiotic use and specific
dietary modifications may provide useful treatment modalities for patients with PD, aiming to
favourably modify the GM composition, by reducing ENS inflammation and α–Syn aggregation, whilst
improving gastrointestinal function.

Controversies and Future Directions
Faecal microbiota transplantation (FMT) was described some 2000 years ago in China, in the treatment
of human gastrointestinal disease [150]. FMT has been increasingly used in the treatment of resistant
Clostridium difficile infection with excellent efficacy and safety [151, 152] and was more recently
trialled in non-PD patients, with marked improvement of constipation [153]. However, little is known
regarding its utility in PD, with only anecdotal reports of benefit [154]. Evolving interest exploring
FMT in PD suggests a possible slowing of disease progression, coupled with potential change in diet
and medication requirement, whilst repopulating the gastrointestinal tract with favourable microbiota
[155]. Prospective longitudinal controlled trials are needed to validate the safety and efficacy potential
of FMT for PD recipients. It is important to note however, that neither pre/probiotics nor FMT appear
to influence the core PD symptoms but, at best, may alter associated disease features such as anxiety,
depression and, of course, constipation.

Further, the scope of gut dysbiosis in PD may be rather more complex and also reflect important
changes in the gut virome, particularly inferred by bacteriophage viruses. A recent study by Tetz et al.,
identified an increased abundance of lactococcus bacteriophage in PD, impacting abundances of lactic
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acid bacteria, known to produce dopamine and regulate intestinal permeability [156]. Ultimately, the
GM may be utilised as an early and minimally invasive PD biomarker, something urgently needed to
provide prodromal or preclinical diagnosis of PD. The most compelling results from across the PD-GM
studies identify increased abundances of Lactobacillaceae (family), Lactobacillus (genus),
Verrucomicrobiaceae (family), Akkermansia (genus) and reduced Prevotellaceae (family), Prevotella
(genus), Lachnospiraceae (family), Blautia, Roseburia, Dorea and Faecalibacterium (genus) in PD
patients [12, 13, 69, 70, 72, 75, 76, 87-93]. These findings suggest significant biological variations that
need to be further explored by a meta-analysis evaluating the influence of confounders, such as
geography and dietary variations, and whether a distinct and consistent GM pattern exists in PD.
Furthermore, lowered Prevotella abundance is not entirely specific to PD, as other conditions including
type I diabetes [157], colon cancer [158] and autism [159], also share reduced Prevotella abundances.
Perhaps inversely, the elevated faecal abundance of Prevotella seen in several studies could be utilised
as a useful biomarker to exclude PD. Interestingly, the canonical signature of GM dysbiosis, reflected
by typically increased abundances of Proteobacteria bacteria [160], was not clearly shown across PDGM studies. Instead, increased abundances of Akkermansia were noted, requiring further evaluation by
meta-analysis.

With expanding interest in the GM and neurodegenerative disorders, next-generation sequencing and
high-throughput taxonomic classification will be an important approach to identify patterns of differing
GM abundances. If coupled with faecal metabolic profiling, the combination of approaches may better
identify useful biomarkers. By identifying disease discriminant biomarkers, faecal microbiota screening
in the community may one day be utilised to identify individuals at-risk of neurological dysfunction, as
well as those with prodromal PD. It would be ideal for these clinical efforts to be complemented by
well-designed pre-clinical models aiming to understand the causal link between GM and PD. This
could lead to the development of novel therapeutic approaches aimed at interfering with α–Syn
aggregation and clearance [161-163].

Conclusion
Across the most recent GM studies in PD, changes in bacterial taxa have been repeatedly shown in
association with disease, endorsing a plausible biological link between the GM and PD [164]. With
increasing acceptance, it appears that these GM changes are implicated and contribute to PD pathology,
rather than a mere consequence of PD-related gut dysfunction. The MGBA interactions are complex
and require ongoing study, although evidence suggests that gut mucosal integrity and permeability,
SCFA metabolism, oxidative stress and inflammation are cardinal to the process [85]. Ultimately, these
mechanisms support α–Syn aggregation within the ENS and subsequent caudorostral cell-to-cell α–Syn
transfer, leading to advancing nigrostriatal dopaminergic network failure, with subsequent overt
manifestation of disease. An improved understanding of the specific attributes and characteristics of the
GM community structures in PD, could lead to more targeted antimicrobial therapies and dietary
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interventions aimed at modulating the GM. However, the frontier is rapidly shifting and future research
needs to challenge these observations by exploring such mechanisms that modulate the GM in PD, as a
viable therapeutic strategy to slow or arrest the spread of disease. If such means are found, it could
unravel a new wave of therapies that target the disease pathophysiology rather than just addressing
symptomatic relief, providing a new direction in PD treatment that is urgently needed.
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Figures:
Figure 1: The Microbiota-Gut-Brian-Axis
Likely implicated pathways in the pathogenesis of Parkinson’s disease. The microbiota-gut-brain-axis
provides a bidirectional communication between a dysbiotic gastrointestinal microbial population,
characterised by increased inflammophiles and the central nervous system, via projections of the vagal
nerve, as well as autonomic and enteric fibres. Abnormal changes in microbial metabolites, namely
SCFAs, as well as the activation of innate immunity via pro-inflammatory cytokines propagate local
inflammation, oxidative stress and increased mucosal permeability, facilitating leakage of bacterial
products into the systemic circulation. These processes lead to abnormal enteric nervous system α–
synuclein deposition and subsequent prion-like spread to the central nervous system, supported by
ongoing activated microglial activity and systemic immune responses.
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Table 1: Summary of Studies Evaluating the Gut Microbiota in Parkinson’s Disease

Table 2: Clinical Correlations of Gut Microbiome Changes in Parkinson’s Disease
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Table 1 – Summary of Studies Evaluating the Gut Microbiota in Parkinson’s Disease
Geographic
Region

Sample size
(n=)

Sequencing

Differences at Family Level

Differences at Genera Level

Cross-sectional studies

Barichella
et al, 2018

Lin et al,
2018

Qian et al,
2018

Italy (Milan)

China
(Guangdong)

China
(Shanghai)

193 PD (39
drug naïve),
22 PSP, 22
MSA and
113 controls

Untargeted

Over-represented in
PD Cases

V3-V4 16S
rRNA gene
sequencing
Illumina
MiSeq

Verrucomicrobiaceae
Enterobacteriaceae,
Christensenellaceae,
Lactobacillaceae,
Coriobacteriaceae,
Bifidobacteriaceae

Bifidobacteriaceae,
Eubacteriaceae,
Aerococcaceae,
Desulfovibrionaceae

75 PD and
45 controls

V4 16S rRNA
gene
sequencing
Illumina HiSeq

45 PD and
45 controls

V3-V4 16S
rRNA gene
sequencing
Illumina
MiSeq

Verrucomicrobiaceae

HeintzBuschart
et al, 2017

Germany
(Kassel)

76 PD and
78 controls

Hill-Burns
et al, 2017

USA
(Seattle,
Atlanta, New
York)

197 PD and
130 controls

16S rRNA
gene
sequencing
Illumina
MiSeq

Bifidobacteriaceae,
Lactobacillaceae,
Tissierellaceae,
Christensenellaceae
Verrucomicrobiaceae

China
(Beijing)

24 PD and
14 controls

V3-V5 16S
rRNA gene
sequencing
Illumina
MiSeq

Enterobacteriaceae,
Veillonellaceae,
Erysipelotrichaceae,
Coriobacteriaceae,
Streptococcaceae,
Moraxellaceae,
Enterococcaceae

Germany
(Bonn)

31 PD and
28 controls.
Male
patients only

Metagenomic
shot gun
sequencing
Illumina HiSeq

29 PD and
29 controls

V1-V2 16S
rRNA gene
sequencing
Illumina
MiSeq

Bedarf et
al, 2017

Hopfner
et al, 2017

Germany
(Kiel)

Lachnospiraceae,

Over-represented in
PD Cases
Akkermansia,
Parabacteroides,
Ruminococcus,
Oscillospira,

Over-represented in
Healthy Controls

Roseburia,

Lachnospiraceae,
Pasteurellaceae,
Streptococcaceae,
Methylobacteriaceae,
Comamonadaceae,
Haolmonadaceae,
Hyphomonadaceae,
Brucellaceae,
Xanthomonadaceae,
Actinomycetaceae,
Sphingomonadaceae,
Micrococcaceae,
Intrasporangiaceae,
Methanobacteriaceae
Idiomarinaceae,
Brevibacteriaceae,
Gemellaceae
Clostridium IV,
Aquabacterium,
Holdemania,
Sphingomonas,
Clostridium XVIII,
Butyricicoccus,
Anaerotruncus

V4 region 16S
rRNA gene
sequencing and
whole
metagenome
shotgun
sequencing
Illumina HiSeq

Li Wei et
al, 2017

Over-represented in
Healthy Controls

Lactobacillaceae,
Barnesiellaceae,
Enterococcaceae

Akkermansia,
Clostridium XIVb,
Anaerotruncus

Lachnospiraceae,
Pasteurellaceae

Bifidobacterium,
Lactobacillus,
Akkermansia

Blautia,
Roseburia,
Faecalibacterium

Acidaminococcus,
Acinetobacter,
Enterococcus,
Escherichia-Shigella,
Megamonas,
Megasphaera,
Proteus,
Streptococcus

Blautia,
Faecalibacterium,
Ruminococcus

Akkermansia,
Unclassified
Bacteria,
Unclassified
Firmicutes

Prevotella,
Eubacterium

Petrov et
al, 2016

Keshavarz
ian et al,
2015

Scheperja
ns et al,
2015

Russia
(Tomsk)

USA
(Chicago)

Finland
(Helsinki)

89 PD and
66 controls

38 PD and
34 controls

72 PD and
72 controls

Unger et
al, 2016

Germany
(Herborn)

34 PD and
34 controls

Hasegawa
et al, 2015

Japan
(Nagoya)

52 PD and
36 controls

V3-V4 16S
rRNA gene
sequencing
Illumina
MiSeq

Christensenella,
Catabacter,
Lactobacillus,
Oscillospira,
Bifidobacterium

Dorea,
Bacteroides,
Prevotella,
Faecalibacterium

Faecal
Bacteroidaceae,
Clostridiaceae,
Verrucomicrobiaceae

Faecal
Lachnospiraceae,
Coprobacillaceae

Faecal
Bacteroides,
Oscillospira,
Akkermansia

Faecal
Blautia,
Coprococcus,
Dorea,
Roseburia

Mucosal
Oxalobacteraceae

Mucosal
Coprobacillaceae

Mucosal
Ralstonia

Mucosal
Faecalibacterium
Dorea

V1-V3 16S
rRNA gene
sequencing
Roche
Pyrosequencing

Lactobacillaceae,
Verrucomicrobiaceae
Bradyrhizobiaceae,
Clostridiales

Prevotellaceae

Targeted

Over-represented in
PD Cases

Over-represented in
Healthy Controls

Over-represented in
PD Cases

Over-represented in
Healthy Controls

Prevotellaceae

Akkermansia
muciniphila,
Bifidobacterium

Faecalibacterium
prausnitzii,
Lactobacillaceae,
Enterococcaceae

V4 16S rRNA
gene
sequencing
Illumina
MiSeq

Quantitative
PCR of
targeted
bacterial
groups
Quantitative
RT-PCR of
16S or 23S
rRNA of 19
bacterial
groups

Enterobacteriaceae

Lactobacillus

Clostridium
coccoides,
Clostridium leptum,
Bacteroides fragilis

Longitudinal studies
Targeted

Minato et
al, 2017

Japan
(Nagoya)

28 PD. No
controls. 2
year follow
up

Quantitative
RT-PCR of
16S or 23S
rRNA of 19
bacterial
groups

Over-represented in
PD Cases

Underrepresented
in PD Cases
Bifidobacterium,
Bacteroides fragilis,
Atopobium,
Bifidobacterium
associated with
various motor and
non-motor features

Table 2 – Clinical Correlations of Gut Microbiome Changes in Parkinson’s Disease
Clinical Effect

Motor Features

Non-Motor
Symptoms

Alteration in the Gastrointestinal
Microbiome
Postural instability and gait difficulty Correlated with the relative abundance of
phenotype
Enterobacteriaceae [12]
Motor complications

Positively associated with Aquabacterium,
Peptococcus and Sphingomonas [90], whilst
Anaerotruncus spp, Clostridium XIVa and
Lachnospiraceae were correlated with (MDSUPDRS) part III scores [88]

Changes in the Unified Parkinson's
Disease Rating Scale Scores

Predicted by lower counts of Bifidobacterium
and Atopobium [13]

Worse clinical phenotype, i.e. higher
frequencies of postural instability,
gait disturbance and cognitive
impairment

Decreased abundances of Lachnospiraceae
and increased Lactobacillaceae and
Christensenellaceae [76]

Depression

Altered abundance of Anaerotruncus spp.
[88]
Higher relative abundance of Christensenella
minuta, Clostridium disporicum and
Oscillibacter valericigenes [101]

Medication Effects

Anxiety

Higher abundance of Clostridium clariflavum
[101]

Cognition (Assessed by the Mini
Mental State Examination)

Positively associated with the genera
Butyricicoccus and Clostridium XIVb [90]

Hallucinations and delusions

Lower counts of Bifidobacterium [13]

Idiopathic Rapid Eye Movement
Sleep Behaviour Disorder. (Not-yet
clinically diagnosed Parkinson’s
disease patients)

Increased abundance of Anaerotruncus and
reduced relative abundance of Prevotellaceae,
suggesting a possible prodromal gut
microbiome change in Parkinson’s disease
[88]

Catechol-O-methyltransferase
inhibitors / anticholinergics

Increased abundances of Lactobacillaceae
and reduced Clostridiales Incertae Sedis IV
[75]

Catechol-O-methyltransferase
inhibitors

Decreased abundances of Firmicutes,
Lachnospiraceae and Ruminococcaceae,
whilst increased abundances of
Actinobacteria, Porphyromonadaceae,
Lactobacillaceae and Proteobacteria [76]

Levodopa

Associated with the abundances of
Bacillaceae [88]

Levodopa equivalent daily dose

Negatively associated with Dorea and
Phascolarctobacterium [90]

